A federal consultative group voted Thursday to relax rules on seven peptides, including BPC-157 and TB-500. The vote was razor-thin. It is not binding. The FDA has given no public comment on whether it will act on the guidance. The move came after weeks of public comment sessions. Wellness backers advocated aggressively for wider access. RFK Jr. was among them. Critics say these compounds have insufficient safety data or help for most uses. The call could redefine how the agency handles a part of the wellness market that is expanding rapidly. Patient groups are waiting to see if the FDA follows through on the vote. A spokesperson offered no clear schedule for a response. Wellness voices argue the change would broaden access to products users find useful. Opponents warn that looser rules could leave gaps in oversight across a fast-moving market. The panel vote only lays the groundwork for change, and the ultimate call rests with the federal agency.